



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7


mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic)



CR1001b : Multiple cervix cancer with cervix tissue array, including pathology grade, TNM and clinical stage, 50 cases/100 cores, replacing CR1001a

Microarray Panel	Multiple cervix carcinoma with cervix tissue microarray, containing 15 cases of adenocarcinoma, 5 adenosquamous carcinoma, 20 squamous cell carcinoma, 4 each cases of cancer adjacent tissue and adjacent normal tissue, 2 cervix tissue, duplicated cores per case		
Cores	100	CR1001b H&E 	
Cases	50		
Row number	10		
Column number	10		
Core Diameter (mm)	1		
Thickness (µm)	5		
Tissue Array Type	FFPE		
Species	Human		
Applications	Routine histology procedures including Immunohistochemistry (IHC) and In Situ Hybridization (ISH), protocols which can be found at our support page.		
Notes	1. TMA slides were sectioned and stored at 4°C and may not be fresh cut, but still suitable for IHC. Please request fresh cut if experiment involves phospho-specific antibodies, RNA studies, FISH or ISH, etc. A minimum of 3 slides per TMA must be purchased to cover the cost of trimming for fresh sectioning. 2. Most TMA slides were not coated with an extra layer of paraffin (tissue cores can be easily seen on the glass). To prevent tissue detachment during antigen retrieval, unbaked slides must be baked for at least 30 to 120 minutes at 60°C. before putting into xylene for de-paraffinization. Baked slides were sent out baked for 2 hours. In the following specsheet, "*" means invalid core; "-" means no applicable or negative in IHC markers.		

	1	2	3	4	5	6	7	8	9	10
A	Cer	Cer	Cer	Cer	Cer	Cer	Cer	Cer	Cer	Cer
B	Cer	Cer	Cer	Cer	Cer	Cer	Cer	Cer	Cer	Cer
C	Cer	Cer	Cer	Cer	Cer	Cer	Cer	Cer	Cer	Cer
D	Cer	Cer	Cer	Cer	Cer	Cer	Cer	Cer	Cer	Cer
E	Cer	Cer	Cer	Cer	Cer	Cer	Cer	Cer	Cer	Cer
F	Cer	Cer	Cer	Cer	Cer	Cer	Cer	Cer	Cer	Cer
G	Cer	Cer	Cer	Cer	Cer	Cer	Cer	Cer	Cer	Cer
H	Cer	Cer	Cer	Cer	Cer	Cer	Cer	Cer	Cer	Cer
I	Cer	Cer	Cer	Cer	Cer	Cer	Cer	Cer	Cer	Cer
J	Cer	Cer	Cer	Cer	Cer	Cer	Cer	Cer	Cer	Adr

Legend: Cer - Cervix

● - AT, ● - Malignant tumor, ● - Malignant tumor (stage I), ● - Malignant tumor (stage IA), ● - Malignant tumor (stage IB), ● - Malignant tumor (stage IB1), ● - Malignant tumor (stage IB2), ● - Malignant tumor (stage II), ● - Malignant tumor (stage IIB), ● - Malignant tumor (stage III), ● - Malignant tumor (stage IIIB), ● - Malignant tumor (stage IVA), ● - NAT, ● - Normal tissue

, tissue IDs are available in exported Excel files.

Pos.	No.	Age	Sex	Organ/Anatomic Site	Pathology diagnosis	TNM	Grade	Stage	Type	Image
A1	1	42	F	Cervix	Adenocarcinoma	T1bN0M0	1	IB	Malignant	
A2	2	42	F	Cervix	Adenocarcinoma	T1bN0M0	1	IB	Malignant	
A3	3	75	F	Cervix	Adenocarcinoma	T1N0M0	1	I	Malignant	
A4	4	75	F	Cervix	Adenocarcinoma	T1N0M0	1	I	Malignant	
A5	5	52	F	Cervix	Adenocarcinoma	T1b2N0M0	1--2	IB2	Malignant	
A6	6	52	F	Cervix	Adenocarcinoma	T1b2N0M0	1--2	IB2	Malignant	
A7	7	48	F	Cervix	Adenocarcinoma	T1N0M0	1--2	I	Malignant	
A8	8	48	F	Cervix	Adenocarcinoma	T1N0M0	1--2	I	Malignant	
A9	9	43	F	Cervix	Adenocarcinoma	T1bN0M0	2	IB	Malignant	
A10	10	43	F	Cervix	Adenocarcinoma	T1bN0M0	2	IB	Malignant	
B1	11	51	F	Cervix	Adenocarcinoma	T1aN0M0	2	IA	Malignant	
B2	12	51	F	Cervix	Adenocarcinoma	T1aN0M0	2	IA	Malignant	
B3	13	41	F	Cervix	Mucinous adenocarcinoma	T1bN0M0	2	IB	Malignant	
B4	14	41	F	Cervix	Mucinous adenocarcinoma	T1bN0M0	2	IB	Malignant	
B5	15	32	F	Cervix	Adenocarcinoma	T1aN0M0	2	IA	Malignant	
B6	16	32	F	Cervix	Adenocarcinoma	T1aN0M0	2	IA	Malignant	
B7	17	72	F	Cervix	Adenocarcinoma	T2bN0M0	2	IIB	Malignant	
B8	18	72	F	Cervix	Adenocarcinoma	T2bN0M0	2	IIB	Malignant	
B9	19	40	F	Cervix	Adenocarcinoma	T1N0M0	2	I	Malignant	
B10	20	40	F	Cervix	Adenocarcinoma	T1N0M0	2	I	Malignant	

C1	21	50	F	Cervix	Adenocarcinoma	T1N1M0	2--3	IIIB	Malignant	
C2	22	50	F	Cervix	Adenocarcinoma	T1N1M0	2--3	IIIB	Malignant	
C3	23	29	F	Cervix	Adenocarcinoma	T2N0M0	2--3	II	Malignant	
C4	24	29	F	Cervix	Adenocarcinoma	T2N0M0	2--3	II	Malignant	
C5	25	34	F	Cervix	Adenocarcinoma	T2bN0M0	2--3	IIB	Malignant	
C6	26	34	F	Cervix	Adenocarcinoma	T2bN0M0	2--3	IIB	Malignant	
C7	27	26	F	Cervix	Endometrioid adenocarcinoma	T1N0M0	3	I	Malignant	
C8	28	26	F	Cervix	Endometrioid adenocarcinoma	T1N0M0	3	I	Malignant	
C9	29	59	F	Cervix	Adenocarcinoma	T1b1N0M0	3	IB1	Malignant	
C10	30	59	F	Cervix	Adenocarcinoma	T1b1N0M0	3	IB1	Malignant	
D1	31	54	F	Cervix	Adenosquamous carcinoma	T1bN0M0	-	IB	Malignant	
D2	32	54	F	Cervix	Adenosquamous carcinoma	T1bN0M0	-	IB	Malignant	
D3	33	38	F	Cervix	Adenosquamous carcinoma	T1bN0M0	-	IB	Malignant	
D4	34	38	F	Cervix	Adenosquamous carcinoma	T1bN0M0	-	IB	Malignant	
D5	35	54	F	Cervix	Adenosquamous carcinoma	T1bN0M0	-	IB	Malignant	
D6	36	54	F	Cervix	Adenosquamous carcinoma	T1bN0M0	-	IB	Malignant	
D7	37	48	F	Cervix	Adenosquamous carcinoma	T3N0M0	-	III	Malignant	
D8	38	48	F	Cervix	Adenosquamous carcinoma	T3N0M0	-	III	Malignant	
D9	39	42	F	Cervix	Adenosquamous carcinoma	T1aN0M0	-	IA	Malignant	
D10	40	42	F	Cervix	Adenosquamous carcinoma	T1aN0M0	-	IA	Malignant	
E1	41	69	F	Cervix	Squamous cell carcinoma	T1bN0M0	1	IB	Malignant	
E2	42	69	F	Cervix	Squamous cell carcinoma	T1bN0M0	1	IB	Malignant	
E3	43	50	F	Cervix	Squamous cell carcinoma	T2bN0M0	1	IIB	Malignant	
E4	44	50	F	Cervix	Squamous cell carcinoma	T2bN0M0	1	IIB	Malignant	
E5	45	53	F	Cervix	Squamous cell carcinoma	T1b2N0M0	1--2	IB2	Malignant	
E6	46	53	F	Cervix	Squamous cell carcinoma	T1b2N0M0	1--2	IB2	Malignant	
E7	47	40	F	Cervix	Squamous cell carcinoma	T1N0M0	1--2	I	Malignant	
E8	48	40	F	Cervix	Squamous cell carcinoma	T1N0M0	1--2	I	Malignant	
E9	49	36	F	Cervix	Squamous cell carcinoma	T1bN1M0	2	IIIB	Malignant	
E10	50	36	F	Cervix	Squamous cell carcinoma	T1bN1M0	2	IIIB	Malignant	
F1	51	33	F	Cervix	Squamous cell carcinoma	T2N0M0	2	II	Malignant	
F2	52	33	F	Cervix	Squamous cell carcinoma	T2N0M0	2	II	Malignant	
F3	53	47	F	Cervix	Squamous cell carcinoma	T2N0M0	2	II	Malignant	
F4	54	47	F	Cervix	Squamous cell carcinoma	T2N0M0	2	II	Malignant	
F5	55	37	F	Cervix	Squamous cell carcinoma	T1bN0M0	2	IB	Malignant	
F6	56	37	F	Cervix	Squamous cell carcinoma	T1bN0M0	2	IB	Malignant	
F7	57	68	F	Cervix	Squamous cell carcinoma	T1bN0M0	2	IB	Malignant	
F8	58	68	F	Cervix	Squamous cell carcinoma	T1bN0M0	2	IB	Malignant	
F9	59	47	F	Cervix	Squamous cell carcinoma	T1N0M0	2	I	Malignant	
F10	60	47	F	Cervix	Squamous cell carcinoma	T1N0M0	2	I	Malignant	
G1	61	62	F	Cervix	Squamous cell carcinoma	T1bN0M0	2	IB	Malignant	
G2	62	62	F	Cervix	Squamous cell carcinoma	T1bN0M0	2	IB	Malignant	
G3	63	39	F	Cervix	Squamous cell carcinoma	T4N0M0	2	IVA	Malignant	
G4	64	39	F	Cervix	Squamous cell carcinoma	T4N0M0	2	IVA	Malignant	
G5	65	27	F	Cervix	Squamous cell carcinoma	T1bN0M0	2	IB	Malignant	
G6	66	27	F	Cervix	Squamous cell carcinoma	T1bN0M0	2	IB	Malignant	
G7	67	32	F	Cervix	Squamous cell carcinoma	T1aN0M0	2	IA	Malignant	
G8	68	32	F	Cervix	Squamous cell carcinoma	T1aN0M0	2	IA	Malignant	
G9	69	76	F	Cervix	Squamous cell carcinoma	T2N0M0	2--3	II	Malignant	
G10	70	76	F	Cervix	Squamous cell carcinoma	T2N0M0	2--3	II	Malignant	
H1	71	43	F	Cervix	Squamous cell carcinoma	T1b1N0M0	2--3	IB1	Malignant	
H2	72	43	F	Cervix	Squamous cell carcinoma	T1b1N0M0	2--3	IB1	Malignant	
H3	73	27	F	Cervix	Squamous cell carcinoma	T1bN0M0	3	IB	Malignant	
H4	74	27	F	Cervix	Squamous cell carcinoma	T1bN0M0	3	IB	Malignant	
H5	75	58	F	Cervix	Squamous cell carcinoma	T1bN0M0	3	IB	Malignant	
H6	76	58	F	Cervix	Squamous cell carcinoma	T1bN0M0	3	IB	Malignant	
H7	77	48	F	Cervix	Squamous cell carcinoma	T1bN0M0	3	IB	Malignant	
H8	78	48	F	Cervix	Squamous cell carcinoma	T1bN0M0	3	IB	Malignant	
H9	79	27	F	Cervix	Squamous cell carcinoma	T1bN0M0	3	IB	Malignant	
H10	80	27	F	Cervix	Squamous cell carcinoma	T1bN0M0	3	IB	Malignant	
I1	81	57	F	Cervix	Cancer adjacent cervix tissue	-	-	-	AT	
I2	82	57	F	Cervix	Cancer adjacent cervix tissue	-	-	-	AT	
I3	83	50	F	Cervix	Cancer adjacent cervix tissue	-	-	-	AT	
I4	84	50	F	Cervix	Cancer adjacent cervix tissue	-	-	-	AT	
I5	85	71	F	Cervix	Cancer adjacent cervix tissue	-	-	-	AT	
I6	86	71	F	Cervix	Cancer adjacent cervix tissue	-	-	-	AT	
I7	87	62	F	Cervix	Cancer adjacent cervix tissue	-	-	-	AT	
I8	88	62	F	Cervix	Cancer adjacent cervix tissue	-	-	-	AT	
I9	89	45	F	Cervix	Adjacent normal cervix tissue	-	-	-	NAT	
I10	90	45	F	Cervix	Adjacent normal cervix tissue	-	-	-	NAT	

J1	91	70	F	Cervix	Adjacent normal cervix tissue	-	-	-	NAT	
J2	92	70	F	Cervix	Adjacent normal cervix tissue	-	-	-	NAT	
J3	93	70	F	Cervix	Adjacent normal cervix tissue	-	-	-	NAT	
J4	94	70	F	Cervix	Adjacent normal cervix tissue	-	-	-	NAT	
J5	95	47	F	Cervix	Adjacent normal cervix tissue	-	-	-	NAT	
J6	96	47	F	Cervix	Adjacent normal cervix tissue	-	-	-	NAT	
J7	97	23	F	Cervix	Cervix tissue	-	-	-	Normal	
J8	98	23	F	Cervix	Cervix tissue	-	-	-	Normal	
J9	99	38	F	Cervix	Cervix tissue	-	-	-	Normal	
J10	100	38	F	Cervix	Cervix tissue	-	-	-	Normal	
-	0	42	M	Adrenal gland	Pheochromocytoma (tissue marker)		-		Malignant	

AMSBIO | www.amsbio.com | info@amsbio.com

AMSBIO LLC
USA & Canada 
1035 Cambridge Street,
Cambridge, MA 02141
T: +1 (617) 945-5033 or
T: +1 (800) 987-0985
F: +1 (617) 945-8218

AMSBIO Europe BV
EU 
Berenkoog 41,
1822 BH Alkmaar,
Netherlands
T: +31 (0) 72 8080244
F: +31 (0) 72 8080142

AMS Biotechnology (Europe) Ltd
UK & Rest of the World 
184 Park Drive, Milton Park
Abingdon OX14 4SE
T: +44 (0) 1235 828 200
F: +44 (0) 1235 820 482

AMS Biotechnology (Europe) Ltd
Switzerland 
Via Lisano 3,
(CP.683)
CH-6900 Massagno
T: +41 (0) 91 604 55 22
F: +41 (0) 91 605 17 85

AMSBIO Europe BV
Deutschland 
T: +49 (0) 69 779099
F: +49 (0) 69 13376880